TPO and autoimmune thrombocytopenic purpura: Japanese treatment guidelines for ITP were revised in 2019, with TPO-RA treatment being repositioned from third-line treatment to second-line treatment [7], which aligns with guidelines from the American Society of Hematology and the International Consensus Report [6, 36].